Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older

References

• Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021 Jul 6; 326(1):35–45. doi: 10.1001/jama.2021.8565
   PubMed Web of Science ®Google Scholar
• Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-Dimer-based Covid-19 vaccine ZF2001 in adults. N Engl J Med. 2022 Jun 2;386(22):2097–2111. doi: 10.1056/NEJMoa2202261
   PubMed Web of Science ®Google Scholar
• Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 2022 Feb 1; 8(1):10. doi: 10.1038/s41421-022-00373-7
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021 Dec 9; 385(24):e84. doi: 10.1056/NEJMoa2114583
   PubMed Web of Science ®Google Scholar
• Falsey AR, Frenck RW Jr., Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021 Oct 21; 385(17):1627–1629. doi: 10.1056/NEJMc2113468
   PubMed Web of Science ®Google Scholar
• Guo W, Duan K, Zhang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine. 2021 Aug;38:101010. doi: 10.1016/j.eclinm.2021.101010
   PubMedGoogle Scholar
• Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022 Apr;22(4):483–495. doi: 10.1016/S1473-3099(21)00681-2
   PubMed Web of Science ®Google Scholar
• Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022 Feb;28(2):401–409. doi: 10.1038/s41591-021-01677-z
   PubMed Web of Science ®Google Scholar
• Jin P, Guo X, Chen W, et al. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial. PLOS Med. 2022 [cited 2022 May 26;19(5):e1003953. doi: 10.1371/journal.pmed.1003953
   PubMed Web of Science ®Google Scholar
• Borobia AM, Carcas AJ, Perez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacs): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021 Jul 10;398(10295):121–130. doi: 10.1016/S0140-6736(21)01420-3
   PubMed Web of Science ®Google Scholar
• Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021 Nov;9(11):1255–1265. doi: 10.1016/S2213-2600(21)00357-X
   PubMed Web of Science ®Google Scholar
• Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 Sep 4;398(10303):856–869. doi: 10.1016/S0140-6736(21)01694-9
   PubMed Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18;398(10318):2258–2276. doi: 10.1016/S0140-6736(21)02717-3
   PubMed Web of Science ®Google Scholar
• Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020 Aug 6;182(3):722–733 e11. doi: 10.1016/j.cell.2020.06.035
   PubMed Web of Science ®Google Scholar
• Kaabi NA, Yang YK, Zhang J, et al. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Signal Transduct Target Ther. 2022 Jun 6; 7(1):172. doi: 10.1038/s41392-022-00984-2
   PubMed Web of Science ®Google Scholar
• Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of immune response after COVID-19 booster vaccination and Association with COVID-19 Omicron infection. JAMA Netw Open. 2022 Sep 1; 5(9):e2231778. doi: 10.1001/jamanetworkopen.2022.31778
   PubMed Web of Science ®Google Scholar
• Liu X, Munro APS, Wright A, et al. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. J Infect. 2023 Jul;87(1):18–26. doi: 10.1016/j.jinf.2023.04.012
   PubMed Web of Science ®Google Scholar
• Jin L, Tang R, Wu S, et al. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCov in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerg Microbes Infect. 2023 Dec;12(1):2155251. doi: 10.1080/22221751.2022.2155251
   PubMed Web of Science ®Google Scholar
• Cao Y, Yisimayi A, Bai Y, et al. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021 Jul;31(7):732–741. doi: 10.1038/s41422-021-00514-9
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021 Aug;21(8):1107–1119. doi: 10.1016/S1473-3099(21)00127-4
   PubMed Web of Science ®Google Scholar
• Juno JA, Wheatley AK. Boosting immunity to COVID-19 vaccines. Nat Med. 2021 Nov;27(11):1874–1875. doi: 10.1038/s41591-021-01560-x
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A, Araki K, et al. From vaccines to memory and back. Immunity. 2010 Oct 29; 33(4):451–463. doi: 10.1016/j.immuni.2010.10.008
   PubMed Web of Science ®Google Scholar
• Liao Y, Chen Y, Chen B, et al. Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac). Front Immunol. 2022;13:1017590. doi: 10.3389/fimmu.2022.1017590
   PubMed Web of Science ®Google Scholar
• Ai J, Zhang H, Zhang Q, et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern. Cell Res. 2022 Jan;32(1):103–106. doi: 10.1038/s41422-021-00590-x
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979–1993. doi: 10.1016/S0140-6736(20)32466-1
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao Z, Cui T, et al. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. Emerg Microbes Infect. 2022 Dec;11(1):829–840. doi: 10.1080/22221751.2022.2048969
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb;590(7847):630–634. doi: 10.1038/s41586-020-03041-6
   PubMed Web of Science ®Google Scholar
• Luo M, Liu Q, Wang J, et al. From SARS to the Omicron variant of COVID-19: China’s policy adjustments and changes to prevent and control infectious diseases. Biosci Trends. 2022 Jan 23; 15(6):418–423. doi: 10.5582/bst.2021.01535
   PubMed Web of Science ®Google Scholar
• He F, Shang X, Ling F, et al. A practice of using five-colour chart to guide the control of COVID-19 and resumption of work in Zhejiang Province, China. Sci Rep. 2021 May 31; 11(1):11317. doi: 10.1038/s41598-021-90808-0
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang Y, Zhang T, et al. Status of and perspectives on COVID-19 vaccination after lifting of the dynamic zero-COVID policy in China. Glob Health Med. 2023 Apr 30;5(2):112–117. doi: 10.35772/ghm.2022.01063
   PubMedGoogle Scholar
• Epidemic Notification from National Health Commission of the People’s Republic of China. [cited 2023 Oct 13]. Available from: http://www.nhc.gov.cn/xcs/yqtb/202212/cf3fb59d2e394ce2b89b5e18c60f5143.shtml
   Google Scholar